海翔药业：参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组

Core Viewpoint - Haishang Pharmaceutical (002099) has announced the initiation of a Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, marking a significant advancement in cancer treatment [1] Group 1: Company Developments - The company received a notification from its subsidiary fund manager, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The investment partnership, Beijing Guoxin Haishang Equity Investment Partnership (Limited Partnership), is participating in the clinical trial of NWRD06 [1] - The trial has officially started at the Chinese Academy of Medical Sciences Cancer Hospital, with the first subject enrolled and administered the drug [1]